secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-01-17T23:59:59+00:00
Accession:  0001493152-25-002832
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma closes $3.5M PIPE offering of pre-funded units and warrants
-------------------------------------------------------------------------

- Sold 2,500,000 Pre-Funded Units at $1.399/unit, raising gross proceeds of $3,497,500.
- Each Pre-Funded Unit includes a pre-funded warrant (exercise $0.001) and 1.5 common warrants (exercise $1.40).
- Amended agreement requires shareholder approval before issuing >19.99% of common stock.
- Placement agents Boustead and D. Boral receive 8% cash commission plus warrants for 175,000 shares at $1.40.
- Offering closed on January 16, 2025; securities sold under Section 4(a)(2) and Rule 506(b).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/0001493152-25-002832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225002832/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-002832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer